Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing [0.03%]
仅通过肿瘤测序检测BRCA1和BRCA2变异的种系测试的有限独立随访
Carol J Nowlen,Molly Daniels,Burak Uzunparmak et al.
Carol J Nowlen et al.
Introduction: Genomic profiling is performed in patients with advanced or metastatic cancer, in order to direct cancer treatment, often sequencing tumor-only, without a matched germline comparator. However, because many o...
Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT Carcinoma [0.03%]
免疫治疗后使用BET抑制剂在一名不可切除的鼻型NUT癌患者中持续临床反应
Harriet Herbison,Sidney Davis,David Nickless et al.
Harriet Herbison et al.
NUT carcinomas (NCs) are a group of rare tumors that can occur anywhere in the body and are defined by the fusion of the nuclear protein in testis (NUTM1) resulting in increased transcription of proto-oncogenes. NCs have a poor prognosis th...
Kavanya Feustel,Jared Martin,Gerald S Falchook
Kavanya Feustel
B7-H3 is a transmembrane receptor highly prevalent on malignant cells and plays an important role in adaptive immunity that is not fully elucidated. Targeted B7-H3 inhibitors, including antibody-drug conjugates, radioimmunotherapy, and mono...
Therapeutic Role of Synthetic Lethality in ARID1A-Deficient Malignancies [0.03%]
在ARID1A缺陷恶性肿瘤中合成致死性的治疗作用
Kyaw Z Hein,Bettzy Stephen,Siqing Fu
Kyaw Z Hein
AT-rich interaction domain 1A (ARID1A), a mammalian switch/sucrose nonfermenting complex subunit, modulates several cellular processes by regulating chromatin accessibility. It is encoded by ARID1A, an immunosuppressive gene frequently disr...
Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab [0.03%]
平均血小板体积与淋巴细胞比率：预测接受尼伏鲁单抗治疗的实体瘤患者反应的新生物标志物
Hasan Cagri Yildirim,Fatih Kus,Deniz Can Guven et al.
Hasan Cagri Yildirim et al.
Introduction: Although immune checkpoint inhibitors (ICIs) are widely used in cancer treatment, identifying factors that predict treatment response remains a challenge in clinical practice. There is a need for biomarkers ...
Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance [0.03%]
PD-1与PD-L1免疫检查点抑制剂的肺部相关不良反应：药物警戒回顾研究
Ugochi Ebinama,Ajay Sheshadri,Kartik Anand et al.
Ugochi Ebinama et al.
Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapeutics. However, immune-related adverse events (irAEs) increase morbidity and mortality and thereby limit therapeutic utility. The real-wo...
Treatment for Advanced Non-Small Lung Cancer (NSCLC) with Mutated EGFR in Low- and Middle-Income Countries (LMICs) [0.03%]
低收入和中等收入国家具有EGFR基因突变的晚期非小细胞肺癌的治疗
Andrés F Cardona,Vaneza Ávila,Oscar Arrieta
Andrés F Cardona
Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer [0.03%]
在一项II期研究中使用PRO-CTCAE评估伊匹单抗治疗激素敏感性前列腺癌的免疫相关不良事件
Daniel Vargas P de Almeida,Justine M Anderson,Daniel C Danila et al.
Daniel Vargas P de Almeida et al.
Introduction: Use of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) during chemotherapy is associated with decreased hospitalization rates, improved quality of lif...
A Review of Scheduling Strategies for Radiotherapy and Immune Checkpoint Inhibition in Locally Advanced Rectal Cancer [0.03%]
局部晚期直肠癌中放疗和免疫检查点抑制联合应用的时间安排策略概述
Lydia Melissourgou-Syka,Michael A Gillespie,Sean M O&#x;Cathail et al.
Lydia Melissourgou-Syka et al.
Colorectal cancer (CRC) is the third most common malignancy across the globe and, despite advances in treatment strategies, survival rates remain low. Rectal cancer (RC) accounts for most of these cases, and traditional management strategie...
Erratum to "Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature" by Soto et al [0.03%]
《免疫检查点抑制剂治疗后的肉芽肿病和气道疾病：病例研究与文献回顾》一文的勘误补充（Soto等人撰写）
[This corrects the article DOI: 10.36401/JIPO-22-30.].